In a dramatic stand-off, Vertex Pharmaceuticals Inc. is refusing to file data with the UK's National Institute for Health and Care Excellence for its latest combination therapy Symkevi (tezacaftor / ivacaftor) until NICE changes how it assesses the cost-effectiveness of its drug.
NICE in turn has suspended its appraisal of the product, saying it will not move on the issue and that...